Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
Andrea Cavazzoni(University of Parma), Andrea Ardizzoni(University of Bologna)
Cited by 45
Related Papers
Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis
|JNCI Journal of the National Cancer Institute|2007|606
PTEN status in advanced colorectal cancer treated with cetuximab
|British Journal of Cancer|2009|85